Rare Disease Trials
OMNI turned a CRO’s toughest recruitment challenge into their most successful studies.
The Results
From Struggle to Success
- 75,000+ rare disease patients recruited
- 50+ studies supported
- 300,000+qualified leads over 4 years
- 299+ total studies enrolled across all conditions
- Unmatched consent and randomization rates
- Ongoing partner of choice for affiliate recruitment
Client Quote (Highlight Block below this section):
“OMNI CRS continues to be the preferred partner for performance-based recruitment.”
The Challenge
A leading CRO specializing in rare diseases faced delays, low enrollment, and high screen failure rates. Traditional tactics weren’t reaching the patients they needed—threatening both timelines and budgets.
- Study Type: Rare disease
- Problem: Low recruitment, missed timelines, poor conversion
- Urgency: High, with sponsors expecting faster enrollment
Why It Worked
Built for the Studies That Struggle to Enroll (left side, with image on right)
OMNI’s unmatched ability to find hard-to-reach patients comes from decades of digital performance experience and a proprietary database of over 500,000 high-intent referrals. For this CRO, it meant faster timelines, higher diversity(?), and more efficient budgets—year after year.
OMNI helped fast-track studies that led to breakthroughs in rare disease research—bringing new therapies closer to the patients who need them most.